Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Spyre Therapeutics, Inc.
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
June 15, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
June 5, 2026
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
June 3, 2026
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 26, 2026
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
May 8, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
May 6, 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
May 6, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
May 6, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
May 6, 2026
1
2
Next Page
→